vs
Side-by-side financial comparison of Fold Holdings, Inc. (FLD) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Fold Holdings, Inc. is the larger business by last-quarter revenue ($9.1M vs $9.1M, roughly 1.0× Protalix BioTherapeutics, Inc.). Protalix BioTherapeutics, Inc. runs the higher net margin — -60.3% vs -379.9%, a 319.6% gap on every dollar of revenue. On growth, Fold Holdings, Inc. posted the faster year-over-year revenue change (8.2% vs -49.9%). Over the past eight quarters, Fold Holdings, Inc.'s revenue compounded faster (36.1% CAGR vs -6.7%).
Fold Holdings, Inc. is a U.S.-based fintech firm specializing in crypto-integrated consumer financial products. Its core offerings include a rewards debit card that provides Bitcoin and other cryptocurrency cashback on routine purchases, alongside user-friendly digital wallet tools for secure crypto storage, serving primarily the North American consumer market.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
FLD vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.1M | $9.1M |
| Net Profit | $-34.7M | $-5.5M |
| Gross Margin | — | 49.4% |
| Operating Margin | -380.0% | -51.1% |
| Net Margin | -379.9% | -60.3% |
| Revenue YoY | 8.2% | -49.9% |
| Net Profit YoY | -7232.4% | -184.8% |
| EPS (diluted) | $-0.02 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.1M | $9.1M | ||
| Q3 25 | $7.4M | $17.9M | ||
| Q2 25 | $8.2M | $15.7M | ||
| Q1 25 | $7.1M | $10.1M | ||
| Q4 24 | $8.4M | $18.2M | ||
| Q3 24 | $5.2M | $18.0M | ||
| Q2 24 | $5.1M | $13.5M | ||
| Q1 24 | $4.9M | — |
| Q4 25 | $-34.7M | $-5.5M | ||
| Q3 25 | $554.2K | $2.4M | ||
| Q2 25 | $13.4M | $164.0K | ||
| Q1 25 | $-48.9M | $-3.6M | ||
| Q4 24 | $486.4K | $6.5M | ||
| Q3 24 | $-62.3M | $3.2M | ||
| Q2 24 | $-2.3M | $-2.2M | ||
| Q1 24 | $-945.0K | — |
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
| Q4 25 | -380.0% | -51.1% | ||
| Q3 25 | 7.5% | 11.9% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | -689.6% | -41.0% | ||
| Q4 24 | -9.1% | 39.6% | ||
| Q3 24 | -15.3% | 22.2% | ||
| Q2 24 | -12.2% | -18.0% | ||
| Q1 24 | -14.7% | — |
| Q4 25 | -379.9% | -60.3% | ||
| Q3 25 | 7.5% | 13.2% | ||
| Q2 25 | 164.2% | 1.0% | ||
| Q1 25 | -689.6% | -35.8% | ||
| Q4 24 | 5.8% | 35.6% | ||
| Q3 24 | -1188.7% | 18.0% | ||
| Q2 24 | -45.1% | -16.4% | ||
| Q1 24 | -19.2% | — |
| Q4 25 | $-0.02 | $-0.06 | ||
| Q3 25 | $0.01 | $0.03 | ||
| Q2 25 | $0.28 | $0.00 | ||
| Q1 25 | $-1.92 | $-0.05 | ||
| Q4 24 | $0.09 | $0.10 | ||
| Q3 24 | $-10.68 | $0.03 | ||
| Q2 24 | $-0.40 | $-0.03 | ||
| Q1 24 | $-0.16 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.7M | $14.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $63.0M | $48.2M |
| Total Assets | $153.5M | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.7M | $14.7M | ||
| Q3 25 | $6.7M | $13.6M | ||
| Q2 25 | $6.6M | $17.9M | ||
| Q1 25 | $11.7M | $19.5M | ||
| Q4 24 | $18.3M | $19.8M | ||
| Q3 24 | — | $27.4M | ||
| Q2 24 | — | $23.4M | ||
| Q1 24 | — | — |
| Q4 25 | $63.0M | $48.2M | ||
| Q3 25 | $94.7M | $52.9M | ||
| Q2 25 | $88.5M | $49.9M | ||
| Q1 25 | $71.9M | $45.2M | ||
| Q4 24 | $-67.8M | $43.2M | ||
| Q3 24 | $-7.4M | $32.4M | ||
| Q2 24 | $-74.0M | $28.6M | ||
| Q1 24 | $-9.4M | — |
| Q4 25 | $153.5M | $82.3M | ||
| Q3 25 | $191.0M | $82.3M | ||
| Q2 25 | $182.1M | $78.5M | ||
| Q1 25 | $148.5M | $73.9M | ||
| Q4 24 | $125.7M | $73.4M | ||
| Q3 24 | $52.2M | $61.6M | ||
| Q2 24 | $51.8M | $91.5M | ||
| Q1 24 | $51.5M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-16.1M | $2.0M |
| Free Cash FlowOCF − Capex | — | $1.6M |
| FCF MarginFCF / Revenue | — | 17.8% |
| Capex IntensityCapex / Revenue | — | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-16.1M | $2.0M | ||
| Q3 25 | $-2.5M | $-3.7M | ||
| Q2 25 | $-4.0M | $-5.2M | ||
| Q1 25 | $-5.0M | $-5.1M | ||
| Q4 24 | $-3.3M | $4.0M | ||
| Q3 24 | $-2.2M | $4.1M | ||
| Q2 24 | $-859.6K | $-3.6M | ||
| Q1 24 | $-354.2K | — |
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | — | $-3.8M | ||
| Q1 24 | — | — |
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | — | -28.1% | ||
| Q1 24 | — | — |
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -4.47× | -1.58× | ||
| Q2 25 | -0.30× | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | -6.82× | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FLD
| Banking And Payment Revenues | $8.4M | 92% |
| Other | $706.0K | 8% |
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
